It has been a mixed year for Inhibrx Biosciences, Inc. insiders: $5.5 million bought by three people and $279,000 sold by one, so more buying than selling overall.
The largest purchase came from Lappe Mark (CEO), about $1.1 million. C-suite participation is part of the picture here.
Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters. Big money check: 163 institutions held INBX as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Lappe Mark | CEO | Buy | 3,324 | $98.87 | $329K | SEC |
| Sep 28, 2026 | Lappe Mark | CEO | Buy | 1,500 | $98.88 | $148K | SEC |
| Sep 28, 2026 | Lappe Mark | CEO | Buy | 2,176 | $99.60 | $217K | SEC |
| Sep 28, 2026 | Lappe Mark | CEO | Buy | 3,000 | $101.70 | $305K | SEC |
| Sep 23, 2026 | Kayyem Jon Faiz | Director | Buy | 5,000 | $100.00 | $500K | SEC |
| Sep 17, 2026 | Kayyem Jon Faiz | Director | Buy | 5,000 | $100.00 | $500K | SEC |
| Sep 15, 2026 | MANHARD KIMBERLY | Director | Sell | 500 | $111.78 | $56K | SEC |
| Sep 15, 2026 | MANHARD KIMBERLY | Director | Sell | 500 | $110.26 | $55K | SEC |
| Sep 15, 2026 | MANHARD KIMBERLY | Director | Sell | 500 | $105.05 | $53K | SEC |
| Sep 10, 2026 | MANHARD KIMBERLY | Director | Sell | 500 | $115.80 | $58K | SEC |
| Sep 10, 2026 | MANHARD KIMBERLY | Director | Sell | 500 | $115.14 | $58K | SEC |
| Sep 8, 2026 | Kayyem Jon Faiz | Director | Buy | 5,000 | $113.52 | $568K | SEC |
| Sep 8, 2026 | FORSYTH DOUGLAS | Director | Buy | 2,500 | $114.65 | $287K | SEC |
| Sep 8, 2026 | Lappe Mark | CEO | Buy | 500 | $108.24 | $54K | SEC |
| Sep 8, 2026 | Lappe Mark | CEO | Buy | 1,219 | $111.88 | $136K | SEC |
In the last 12 months Inhibrx Biosciences, Inc. insiders made open-market purchases worth about $5.5 million and sales worth about $279,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in INBX was filed on 2026-09-28.
163 investment managers reported holding INBX in SEC Form 13F filings for Q2 2026.
No congressional trades in INBX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).